JP2020510426A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020510426A5 JP2020510426A5 JP2019546855A JP2019546855A JP2020510426A5 JP 2020510426 A5 JP2020510426 A5 JP 2020510426A5 JP 2019546855 A JP2019546855 A JP 2019546855A JP 2019546855 A JP2019546855 A JP 2019546855A JP 2020510426 A5 JP2020510426 A5 JP 2020510426A5
- Authority
- JP
- Japan
- Prior art keywords
- rna
- region
- protein
- mrna
- coding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022209557A JP2023052106A (ja) | 2017-02-28 | 2022-12-27 | 翻訳可能分子およびその合成 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762465073P | 2017-02-28 | 2017-02-28 | |
| US62/465,073 | 2017-02-28 | ||
| PCT/US2018/020018 WO2018160592A1 (en) | 2017-02-28 | 2018-02-27 | Translatable molecules and synthesis thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022209557A Division JP2023052106A (ja) | 2017-02-28 | 2022-12-27 | 翻訳可能分子およびその合成 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020510426A JP2020510426A (ja) | 2020-04-09 |
| JP2020510426A5 true JP2020510426A5 (enExample) | 2021-04-15 |
| JP7674077B2 JP7674077B2 (ja) | 2025-05-09 |
Family
ID=63370513
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019546855A Active JP7674077B2 (ja) | 2017-02-28 | 2018-02-27 | 翻訳可能分子およびその合成 |
| JP2022209557A Pending JP2023052106A (ja) | 2017-02-28 | 2022-12-27 | 翻訳可能分子およびその合成 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022209557A Pending JP2023052106A (ja) | 2017-02-28 | 2022-12-27 | 翻訳可能分子およびその合成 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US11407800B2 (enExample) |
| EP (1) | EP3589290A4 (enExample) |
| JP (2) | JP7674077B2 (enExample) |
| WO (1) | WO2018160592A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7674077B2 (ja) | 2017-02-28 | 2025-05-09 | アークトゥラス・セラピューティクス・インコーポレイテッド | 翻訳可能分子およびその合成 |
| AU2019394996B2 (en) | 2018-12-06 | 2025-11-06 | Arcturus Therapeutics, Inc. | Compositions and methods for treating ornithine transcarbamylase deficiency |
| CN110331147A (zh) * | 2019-06-21 | 2019-10-15 | 苏州吉玛基因股份有限公司 | 一种mRNA的制备方法及其在肿瘤治疗中的应用 |
| WO2021178510A1 (en) | 2020-03-03 | 2021-09-10 | Arcturus Therapeutics, Inc. | Compositions and methods for the treatment of ornithine transcarbamylase deficiency |
| AU2021233816A1 (en) | 2020-03-09 | 2022-10-06 | Arcturus Therapeutics, Inc. | Coronavirus vaccine compositions and methods |
| JP2023524071A (ja) | 2020-05-01 | 2023-06-08 | アークトゥラス・セラピューティクス・インコーポレイテッド | 嚢胞性線維症を治療するための核酸及び方法 |
| BR112023002642A2 (pt) | 2020-08-14 | 2023-04-04 | Arcturus Therapeutics Inc | Método para liofilizar nanopartículas lipídicas |
| CA3128660A1 (en) * | 2020-10-09 | 2022-04-09 | Eric G. Marcusson | Compositions and methods for the prevention and/or treatment of covid-19 |
| CN113372432A (zh) * | 2021-06-15 | 2021-09-10 | 深圳市臻质医疗科技有限公司 | 一种基于化学修饰mRNA编码蛋白因子诱导和/或增强软骨损伤修复的方法 |
| AU2023274159A1 (en) * | 2022-09-07 | 2024-03-21 | Eyegene Inc. | COMPOSITION FOR IN-VIVO DELIVERING mRNA CONTAINING MODIFIED NUCLEOTIDE |
| KR102785258B1 (ko) * | 2022-09-07 | 2025-03-26 | 아이진 주식회사 | 변형핵산 함유 mRNA의 체내 전달용 조성물 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE50214201D1 (de) | 2001-06-05 | 2010-03-25 | Curevac Gmbh | Stabilisierte mRNA mit erhöhtem G/C-Gehalt, enkodierend für ein bakterielles Antigen sowie deren Verwendung |
| AU2002338926B2 (en) * | 2001-11-05 | 2007-05-24 | Janssen Pharmaceutica N.V. | Method for the in vitro synthesis of short double stranded RNAs |
| HUE043492T2 (hu) * | 2005-08-23 | 2019-08-28 | Univ Pennsylvania | Módosított nukleozidokat tartalmazó RNS és eljárások az alkalmazására |
| US8304529B2 (en) | 2006-07-28 | 2012-11-06 | Life Technologies Corporation | Dinucleotide MRNA cap analogs |
| WO2009058911A2 (en) | 2007-10-31 | 2009-05-07 | Applied Biosystems Inc. | Preparation and isolation of 5' capped mrna |
| US20090226906A1 (en) | 2008-03-05 | 2009-09-10 | Helicos Biosciences Corporation | Methods and compositions for reducing nucleotide impurities |
| EP2763701B1 (en) | 2011-10-03 | 2018-12-19 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| US9283287B2 (en) * | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
| BR122019025681B1 (pt) | 2012-11-01 | 2023-04-18 | Factor Bioscience Inc | Método para inserir uma sequência de ácido nucleico em uma localização segura de um genoma de uma célula |
| CA2892529C (en) * | 2012-11-26 | 2023-04-25 | Moderna Therapeutics, Inc. | Terminally modified rna |
| KR102354389B1 (ko) | 2013-08-21 | 2022-01-20 | 큐어백 아게 | Rna―암호화된 단백질의 발현을 증가시키는 방법 |
| EP3052511A4 (en) | 2013-10-02 | 2017-05-31 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
| WO2015061491A1 (en) | 2013-10-22 | 2015-04-30 | Shire Human Genetic Therapies, Inc. | Mrna therapy for phenylketonuria |
| GB201403096D0 (en) | 2014-02-21 | 2014-04-09 | Oxford Nanopore Tech Ltd | Sample preparation method |
| US20160130567A1 (en) * | 2014-11-02 | 2016-05-12 | Arcturus Therapeutics, Inc. | Messenger una molecules and uses thereof |
| EP3041948B1 (en) | 2014-11-10 | 2019-01-09 | Modernatx, Inc. | Alternative nucleic acid molecules containing reduced uracil content and uses thereof |
| WO2016077123A1 (en) * | 2014-11-10 | 2016-05-19 | Moderna Therapeutics, Inc. | Multiparametric nucleic acid optimization |
| US20190382774A1 (en) * | 2016-05-18 | 2019-12-19 | Modernatx, Inc. | Polyribonucleotides containing reduced uracil content and uses thereof |
| JP7674077B2 (ja) | 2017-02-28 | 2025-05-09 | アークトゥラス・セラピューティクス・インコーポレイテッド | 翻訳可能分子およびその合成 |
-
2018
- 2018-02-27 JP JP2019546855A patent/JP7674077B2/ja active Active
- 2018-02-27 WO PCT/US2018/020018 patent/WO2018160592A1/en not_active Ceased
- 2018-02-27 EP EP18761078.7A patent/EP3589290A4/en active Pending
- 2018-02-27 US US15/907,123 patent/US11407800B2/en active Active
-
2022
- 2022-07-14 US US17/812,576 patent/US11939363B2/en active Active
- 2022-12-27 JP JP2022209557A patent/JP2023052106A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020510426A5 (enExample) | ||
| Tusup et al. | Design of in vitro transcribed mRNA vectors for research and therapy | |
| JP2010530245A5 (enExample) | ||
| AU2017226199A1 (en) | Virus vectors expressing multiple epitopes of tumor associated antigens for inducing antitumor immunity | |
| JP2008056679A5 (enExample) | ||
| WO2013018778A1 (ja) | ウィルムス腫瘍遺伝子産物またはその断片をコードしている改変型核酸構築物を含んでいる免疫治療用細胞、当該細胞の製造方法、および当該核酸構築物 | |
| JP2004501646A5 (enExample) | ||
| WO2023227124A1 (zh) | 一种构建mRNA体外转录模板的骨架 | |
| CN106459997A (zh) | 用于疫苗应用的高效价病毒样囊泡的进化 | |
| WO2023035372A1 (zh) | 一种有限自我复制mRNA分子系统、制备方法及应用 | |
| WO2018212361A1 (en) | Method of treating diseases associated with myd88 pathways using crispr-gndm system | |
| CN115485379A (zh) | 用于体外mRNA转录的合成DNA模板 | |
| JP2025114633A (ja) | インビトロトランスクリプトｍｒｎａ及びこれを含有する薬学組成物 | |
| EP3158060B1 (en) | Method for rapid generation of an infectious rna virus | |
| JP2025520106A (ja) | Ｍｒｎａの細胞内安定性と生合成を向上させるｕｔｒ配列を含む構成物とその使用 | |
| WO2024209218A1 (en) | Coronavirus vaccines inducing broad immunity against variants | |
| CN120641560A (zh) | Rna聚合酶变体及其应用 | |
| WO2023208118A9 (zh) | 核酸构建体及其应用 | |
| CN110577972B (zh) | CRISPR/Sa-ShaCas9基因编辑系统及其应用 | |
| JP2024509146A (ja) | コロナウイルスに対して保護するためのワクチン産生のための完全合成長鎖核酸 | |
| Saini et al. | High-level synthesis of Johnson grass mosaic virus coat protein in Escherichia coli and its auto-assembly to form virus-like particles | |
| CN112725378A (zh) | 一种人工改造的akt3环状rna及其在新冠疫苗中的应用 | |
| JPWO2023066874A5 (enExample) | ||
| JP2006501166A5 (enExample) | ||
| CN117940154A (zh) | 产生编码患者肿瘤新抗原的双链dna池的方法 |